Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02952248
Title A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

urinary bladder cancer

triple-receptor negative breast cancer

ovarian cancer

Advanced Solid Tumor

stomach cancer

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Therapies

Ezabenlimab

Age Groups: senior | adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Florida Cancer Specialists Sarasota Florida 34232 United States Details
Ingalls Memorial Hospital Harvey Illinois 60426 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Greenville Health System Greenville South Carolina 29605 United States Details
Tennessee Oncology, PLLC Nashville Tennessee 37203 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Juravinski Cancer Centre - Hamilton Health Sciences Hamilton Ontario L8V 5C2 Canada Details
The Ottawa Hospital Ottawa Ontario K1H 8L6 Canada Details
Princess Margaret Cancer Centre Toronto Ontario M5G 2M9 Canada Details
Centre Hospitalier de l'Universite de Montreal (CHUM) Montreal Quebec H2X 0A9 Canada Details
Sarah Cannon Research Institute London W1G 6AD United Kingdom Details
The Christie Hospital Manchester M20 4BX United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field